Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy

Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimura, Taku, Tanita, Kayo, Sato, Yota, Kambayashi, Yumi, Furudate, Sadanori, Tsukada, Akira, Hashimoto, Akira, Aiba, Setsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836287/
https://www.ncbi.nlm.nih.gov/pubmed/29515406
http://dx.doi.org/10.1159/000486278
_version_ 1783303936341442560
author Fujimura, Taku
Tanita, Kayo
Sato, Yota
Kambayashi, Yumi
Furudate, Sadanori
Tsukada, Akira
Hashimoto, Akira
Aiba, Setsuya
author_facet Fujimura, Taku
Tanita, Kayo
Sato, Yota
Kambayashi, Yumi
Furudate, Sadanori
Tsukada, Akira
Hashimoto, Akira
Aiba, Setsuya
author_sort Fujimura, Taku
collection PubMed
description Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy.
format Online
Article
Text
id pubmed-5836287
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-58362872018-03-07 Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy Fujimura, Taku Tanita, Kayo Sato, Yota Kambayashi, Yumi Furudate, Sadanori Tsukada, Akira Hashimoto, Akira Aiba, Setsuya Case Rep Oncol Case Report Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy. S. Karger AG 2018-01-16 /pmc/articles/PMC5836287/ /pubmed/29515406 http://dx.doi.org/10.1159/000486278 Text en Copyright © 2018 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Fujimura, Taku
Tanita, Kayo
Sato, Yota
Kambayashi, Yumi
Furudate, Sadanori
Tsukada, Akira
Hashimoto, Akira
Aiba, Setsuya
Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
title Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
title_full Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
title_fullStr Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
title_full_unstemmed Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
title_short Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
title_sort successful treatment of erythrodermic mycosis fungoides with mogamulizumab followed by etoposide monotherapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836287/
https://www.ncbi.nlm.nih.gov/pubmed/29515406
http://dx.doi.org/10.1159/000486278
work_keys_str_mv AT fujimurataku successfultreatmentoferythrodermicmycosisfungoideswithmogamulizumabfollowedbyetoposidemonotherapy
AT tanitakayo successfultreatmentoferythrodermicmycosisfungoideswithmogamulizumabfollowedbyetoposidemonotherapy
AT satoyota successfultreatmentoferythrodermicmycosisfungoideswithmogamulizumabfollowedbyetoposidemonotherapy
AT kambayashiyumi successfultreatmentoferythrodermicmycosisfungoideswithmogamulizumabfollowedbyetoposidemonotherapy
AT furudatesadanori successfultreatmentoferythrodermicmycosisfungoideswithmogamulizumabfollowedbyetoposidemonotherapy
AT tsukadaakira successfultreatmentoferythrodermicmycosisfungoideswithmogamulizumabfollowedbyetoposidemonotherapy
AT hashimotoakira successfultreatmentoferythrodermicmycosisfungoideswithmogamulizumabfollowedbyetoposidemonotherapy
AT aibasetsuya successfultreatmentoferythrodermicmycosisfungoideswithmogamulizumabfollowedbyetoposidemonotherapy

Ejemplares similares